Skip to main content
Clinical Trials/NCT02125669
NCT02125669CompletedNot Applicable

The Role of the 595 nm Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas at Low Risk Anatomical Sites: Outcome of a Double Blind Randomized Placebo Controlled Trial

Hautklinik Darmstadt0 sites100 target enrollmentStarted: November 1, 2012Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
100
Primary Endpoint
complete response

Study Overview

Brief Summary

Pulsed dye laser (PDL) treatments have been suggested to be a safe and effective therapeutic approach for treating basal cell carcinomas. Robust supporting evidence is, however, lacking due to inconsistent design of available studies. The purpose of this study is to evaluate the PDL's efficacy and safety in treating superficial basal cell carcinoma (sBCC) at low risk anatomical sites in an evidence based study setting.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • histologically confirmed unpigmented sBCC on the trunk and extremities
  • maximal tumour diameter 30 mm

Exclusion Criteria

  • Fitzpatrick skin type >III
  • pregnancy
  • previous BCC treatment within 4 weeks
  • coagulation disorders
  • photo sensitizing medication
  • any indication of poor compliance

Outcomes

Primary Outcomes

complete response

Time Frame: 9 months

Secondary Outcomes

  • patients satisfaction(9 months)
  • side effects(9 months)
  • reduction of tumor diameter and tumor thickness(9 months)

Investigators

Sponsor
Hautklinik Darmstadt
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Maurizio Podda

PD Dr. med.

Hautklinik Darmstadt

Similar Trials

Pulsed Dye Laser in Treating Superficial... | Clinical Trial